• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

J&J’s Evarrest fibrin sealant patch wins expanded indication for hemostasis

December 2, 2016 By Sarah Faulkner

J&J's Evarrest fibrin sealant patch wins expanded indication for hemostasisJohnson & Johnson (NYSE:JNJ) subsidiary Ethicon said today that the FDA approved an expanded indication for its Evarrest fibrin sealant patch as an supplementary hemostat.

With the expanded indication, the patch can be used with manual compression as an adjunct to hemostasis in adult surgery patients, when standard surgical techniques to control bleeding such as suture or ligature are ineffective. The fibrin sealant patch uses biologics to rapidly stop problematic bleeding while a patient is undergoing surgery. The drug device reacts human thrombin and fibrinogen to form a fibrin clot, providing a structure for clot formation.

The clinical study that supported the FDA’s decision to expand Evarrest’s indication compared it to Tachosil fibrin sealant patch in a head-to-head comparison. The cardiovascular trial demonstrated that Evarrest had superior hemostatic efficacy. The patch also outperforms conventional supplementary hemostatic methods and delivers cost savings compared with the current standard of care, the J&J subsidiary said.

“The general hemostasis indication for Evarrest offers surgeons expanded options for safe and effective adjunctive hemostasis,” Ethicon’s worldwide VP of biosurgicals Oray Boston said in prepared remarks. “Ethicon offers a comprehensive portfolio of best-in-class surgical products and Evarrest is just one of many examples of how our science-based innovative solutions and high quality technologies enable surgeons to achieve superior hemostatic efficacy and improve patient care.”

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance, Surgical Tagged With: Ethicon, johnsonandjohnson

IN CASE YOU MISSED IT

  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS